Update in the Management of Extraintestinal Manifestations of Inflammatory Bowel Disease

[1]  Richard Hansen,et al.  Microbiota of De-Novo Pediatric IBD: Increased Faecalibacterium Prausnitzii and Reduced Bacterial Diversity in Crohn's But Not in Ulcerative Colitis , 2012, The American Journal of Gastroenterology.

[2]  E. Doménech,et al.  Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. , 2011, Inflammatory bowel diseases.

[3]  T. Louis,et al.  Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. , 2011, Ophthalmology.

[4]  D. M. van der Heijde,et al.  IBD and arthropathies: a practical approach to its diagnosis and management , 2011, Gut.

[5]  G. Gores,et al.  Diagnosis and management of primary sclerosing cholangitis , 2010, Hepatology.

[6]  R. Kozarek,et al.  A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis , 2008, Journal of clinical gastroenterology.

[7]  K. Khosrotehrani,et al.  Significance of Erythema Nodosum and Pyoderma Gangrenosum in Inflammatory Bowel Diseases: A Cohort Study of 2402 Patients , 2008, Medicine.

[8]  Paul Wordsworth,et al.  Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). , 2008, The Journal of rheumatology.

[9]  R. Chapman,et al.  An update on primary sclerosing cholangitis , 2008, Current opinion in gastroenterology.

[10]  K. Boberg,et al.  The natural history of small-duct primary sclerosing cholangitis. , 2008, Gastroenterology.

[11]  A. Befeler,et al.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis , 2007, Current gastroenterology reports.

[12]  M. Zierhut,et al.  Adalimumab in the therapy of uveitis in childhood , 2006, British Journal of Ophthalmology.

[13]  D. Levy,et al.  Favorable response to high-dose infliximab for refractory childhood uveitis. , 2006, Ophthalmology.

[14]  R. Chapman,et al.  High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. , 2006, Journal of hepatology.

[15]  W. Sandborn,et al.  Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  K. Boberg,et al.  High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. , 2005, Gastroenterology.

[17]  A. Forbes,et al.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial , 2005, Gut.

[18]  G. Gores,et al.  Liver Transplantation with Neoadjuvant Chemoradiation is More Effective than Resection for Hilar Cholangiocarcinoma , 2005, Annals of surgery.

[19]  M. Dougados,et al.  ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2005, Annals of the rheumatic diseases.

[20]  J. Reichrath,et al.  Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. , 2005, Journal of the American Academy of Dermatology.

[21]  J. Braun,et al.  Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. , 2005, Arthritis and rheumatism.

[22]  Justine R. Smith,et al.  A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. , 2005, Archives of ophthalmology.

[23]  M. Manns,et al.  Characterization, Outcome, and Prognosis in 273 Patients with Primary Sclerosing Cholangitis: A Single Center Study , 2005, The American Journal of Gastroenterology.

[24]  R. Allan,et al.  Oral ulceration – aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic , 2003, Alimentary pharmacology & therapeutics.

[25]  G. Rogler,et al.  Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease , 2002, American Journal of Gastroenterology.

[26]  D. Jewell,et al.  Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. , 2002, Gastroenterology.

[27]  P. Heidenreich,et al.  Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. , 2002, Gastrointestinal endoscopy.

[28]  I. Bjarnason,et al.  Inflammatory bowel disease and spondylarthropathy. , 2001, Arthritis and rheumatism.

[29]  Nancy Xiaonan Yu,et al.  The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study , 2001, American Journal of Gastroenterology.

[30]  N. Chalasani,et al.  Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. , 2001, Gastrointestinal endoscopy.

[31]  Aj Smith,et al.  Topical tacrolimus in the management of peristomal pyoderma gangrenosum , 2001, The Journal of dermatological treatment.

[32]  M. De Vos,et al.  Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. , 2000, The Journal of rheumatology.

[33]  R. V. Van Gelder,et al.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. , 2000, American journal of ophthalmology.

[34]  D. Jabs,et al.  Episcleritis and scleritis: clinical features and treatment results. , 2000, American journal of ophthalmology.

[35]  J. Braun,et al.  Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. , 2000, Arthritis and rheumatism.

[36]  B. Petersen,et al.  Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[37]  G. Gores,et al.  Long‐term results of patients undergoing liver transplantation for primary sclerosing cholangitis , 1999, Hepatology.

[38]  M. A. van de Laar,et al.  Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. , 1999, The Journal of rheumatology.

[39]  A. Khandwala,et al.  Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. , 1997, Compendium of continuing education in dentistry.

[40]  K. Lindor.  Ursodiol for Primary Sclerosing Cholangitis , 1997 .

[41]  R. Greer,et al.  A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. , 1993, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[42]  R. Wiesner,et al.  Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis , 1991, Seminars in liver disease.

[43]  E. Gravallese,et al.  Arthritic manifestations of inflammatory bowel disease. , 1988, The American journal of gastroenterology.

[44]  D. Sachar,et al.  THE EXTRA-INTESTINAL COMPLICATIONS OF CROHN'S DISEASE AND ULCERATIVE COLITIS: A STUDY OF 700 PATIENTS , 1976, Medicine.

[45]  O. Chosidow,et al.  Is topical monotherapy effective for localized pyoderma gangrenosum? , 2011, Archives of dermatology.

[46]  D. Weedon.  The vasculopathic reaction pattern , 2010 .

[47]  R. Wiesner,et al.  Excellent long-term survival following liver transplantation in primary sclerosing cholangitis patients , 1998 .

[48]  K. Lindor.  Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. , 1997, The New England journal of medicine.